Correction: Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from second-line immunotherapy in NSCLC

BMC Med Res Methodol. 2023 Jan 27;23(1):26. doi: 10.1186/s12874-023-01850-7.

R K Ismail^{1

2

3}, F M N H Schramel⁴, M van Dartel⁵, A M G Pasmooij⁵, C M Cramer-van der Welle⁶, D L Hilarius⁷, A de Boer^{8

5}, M W J M Wouters^{9

10}, E M W van de Garde^{8

11}

¹ Dutch Institute for Clinical Auditing, Leiden, the Netherlands. r.ismail@dica.nl.
² Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands. r.ismail@dica.nl.
³ Medicines Evaluation Board, Utrecht, The Netherlands. r.ismail@dica.nl.
⁴ Department of Pulmonary Diseases, St Antonius Hospital, Nieuwegein, The Netherlands.
⁵ Medicines Evaluation Board, Utrecht, The Netherlands.
⁶ Santeon Hospital Group, Utrecht, The Netherlands.
⁷ Department of Clinical Pharmacy, Rode Kruis Hospital, Beverwijk, The Netherlands.
⁸ Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands.
⁹ Dutch Institute for Clinical Auditing, Leiden, the Netherlands.
¹⁰ Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands.
¹¹ Department of Clinical Pharmacy, St Antonius Hospital, Nieuwegein, Utrecht, The Netherlands.

No abstract available

Publication types